Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Operating Expenses (2020 - 2025)

Barinthus Biotherapeutics' Operating Expenses history spans 6 years, with the latest figure at $11.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 50.91% year-over-year to $11.6 million; the TTM value through Dec 2025 reached $71.1 million, down 15.52%, while the annual FY2025 figure was $71.1 million, 15.52% down from the prior year.
  • Operating Expenses reached $11.6 million in Q4 2025 per BRNS's latest filing, down from $15.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $31.6 million in Q4 2022 to a low of -$1.1 million in Q3 2022.
  • Average Operating Expenses over 5 years is $16.7 million, with a median of $17.0 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: tumbled 119.28% in 2022, then skyrocketed 1603.73% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $16.7 million in 2021, then soared by 89.3% to $31.6 million in 2022, then tumbled by 36.65% to $20.0 million in 2023, then rose by 17.94% to $23.6 million in 2024, then plummeted by 50.91% to $11.6 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Operating Expenses are $11.6 million (Q4 2025), $15.2 million (Q3 2025), and $23.3 million (Q2 2025).